Latest News

MSD partnership boosts Bionomics August 17, 2017

Adelaide-based Bionomics has reported strong revenue growth on the back of its agreement with MSD for the discovery and development of therapies for the treatment of chronic and neuropathic pain.

CSL hurt by high expectations August 17, 2017

High expectations do not always help and that is certainly the case for CSL. The company reported its full year 2017 results yesterday, announcing a 15 per cent increase in revenue...

Prota reports positive results from follow-up study August 17, 2017

Allergy immunotherapy company Prota Therapeutics has announced results from a follow up study of the probiotic and peanut immunotherapy (PPOIT) treatment licensed from the Murdoch Childrens Research Institute.

Response to IP report moving closer August 17, 2017

The life sciences sector, in Australia and overseas, is anticipating the Turnbull government's response to the Productivity Commission's report into Australia's intellectual property arrangements.

Winning one part of the drug development process August 15, 2017

Dr James Garner joined Sydney-based oncology-focussed biotechnology company Novogen in early 2016 after an extensive career with multinational life sciences companies in development and commercialisation roles.

Perth-based biotech resurrects cancer therapy August 15, 2017

A Perth-based biotechnology company is close to commercialising a new cancer therapy more than three decades after it was discovered by a company that, after a series of mergers, ended up as part of Pfizer.

SA award for LBT Innovations August 15, 2017

LBT Innovations has been awarded the 2017 SA Science Excellence Award for 'Excellence in Research Collaboration'.

Opthea presents additional data from OPT-302 trial August 15, 2017

Opthea (ASX:OPT) has announced positive results from its Phase 1/2a clinical trial of OPT-302, a novel VEGF-C/D ‘Trap’ therapy for wet age-related macular degeneration.

Australian manufacturing licence for AusCann August 10, 2017

AusCann (ASX:AC8) has announced it has been granted an Australian manufacturing licence authorising the manufacture and supply of medicinal cannabis under the Narcotic Drugs Act 1967.

Starpharma and Monash awarded STEM+ Business fellowships August 10, 2017

Starpharma (ASX:SPL) and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows.

Immuron approved to commence new study August 10, 2017

Australian microbiome biopharmaceutical company Immuron (ASX:IMC) has been granted final approval to commence its first in-human IMM-529 clinical study for the treatment of Clostridium Difficile Infection.

ResApp reports preliminary top-line results from SMARTCOUGH-C study August 10, 2017

In the final data review, prior to the un-blinding of the study data, ResApp identified at least two issues with the clinical data.

Most Read

New Stories

MSD partnership boosts Bionomics

PhD mentoring program rolls out across Australia

CSL hurt by high expectations

Prota reports positive results from follow-up study

Response to IP report moving closer

Winning one part of the drug development process

Perth-based biotech resurrects cancer therapy

Sign In